Raleigh Capital Management Inc. Has $1.56 Million Stock Holdings in Sanofi (NASDAQ:SNY)

Raleigh Capital Management Inc. decreased its position in Sanofi (NASDAQ:SNY) by 1.2% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 32,435 shares of the company’s stock after selling 406 shares during the period. Raleigh Capital Management Inc.’s holdings in Sanofi were worth $1,564,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of the business. Northwest Investment Counselors LLC acquired a new position in shares of Sanofi during the 3rd quarter worth about $29,000. Concord Wealth Partners lifted its holdings in shares of Sanofi by 157.8% in the third quarter. Concord Wealth Partners now owns 593 shares of the company’s stock valued at $34,000 after purchasing an additional 363 shares in the last quarter. Fortitude Family Office LLC boosted its position in Sanofi by 708.6% during the 3rd quarter. Fortitude Family Office LLC now owns 752 shares of the company’s stock worth $43,000 after acquiring an additional 659 shares during the last quarter. Sunbelt Securities Inc. boosted its holdings in Sanofi by 72.1% during the third quarter. Sunbelt Securities Inc. now owns 747 shares of the company’s stock worth $43,000 after purchasing an additional 313 shares during the last quarter. Finally, Versant Capital Management Inc acquired a new position in shares of Sanofi during the 4th quarter worth about $54,000. Institutional investors and hedge funds own 14.04% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, StockNews.com cut shares of Sanofi from a “buy” rating to a “hold” rating in a research note on Thursday, December 12th. Two investment analysts have rated the stock with a hold rating, one has given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $57.50.

Sanofi Stock Performance

Shares of SNY stock opened at $51.51 on Thursday. Sanofi has a 52 week low of $45.22 and a 52 week high of $58.97. The company has a market capitalization of $130.72 billion, a price-to-earnings ratio of 26.28, a PEG ratio of 1.19 and a beta of 0.57. The company has a 50-day simple moving average of $48.53 and a 200 day simple moving average of $52.16. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.65 and a current ratio of 1.00.

Sanofi (NASDAQ:SNY) last released its quarterly earnings results on Friday, October 25th. The company reported $1.57 EPS for the quarter, beating the consensus estimate of $0.22 by $1.35. Sanofi had a net margin of 9.96% and a return on equity of 27.45%. The business had revenue of $13.44 billion for the quarter, compared to the consensus estimate of $16.59 billion. During the same period in the prior year, the company posted $2.55 earnings per share. Sanofi’s revenue was up 12.3% compared to the same quarter last year. On average, sell-side analysts predict that Sanofi will post 3.82 earnings per share for the current year.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.